We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ToolsNew Trading Tool: Live US Options Flow! Try it out.
Our engineers are aware of and working on the problem with on-site streaming.
Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.425 | -2.56% | 16.20 | 489,492 | 16:35:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 16.25 | 16.50 | 16.625 | 16.375 | 16.625 | |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0.00 | -2.07 | -0.30 | - | 132.07 |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:19 | UT | 8,100 | 16.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/9/2023 | 14:32 | ALNC |  Scancell celebrates "positive" clinical trial data for cancer vaccine |
| 19/9/2023 | 07:00 | UKREG | Scancell Holdings Plc Positive data from Phase 2 SCOPE trial with SCIB1 |
| 14/9/2023 | 07:00 | UKREG | Scancell Holdings Plc Scancell to present three posters at ICI |
| 07/9/2023 | 07:00 | UKREG | Scancell Holdings Plc Scancell Appoints Head of Business Development |
| 29/8/2023 | 09:53 | ALNC | IN BRIEF: Scancell appoints Prenetics' Sath Nirmalananthan as new CFO |
| 29/8/2023 | 07:00 | UKREG | Scancell Holdings Plc Scancell Appoints Sath Nirmalananthan as CFO |
| 31/7/2023 | 10:23 | ALNC | Scancell shares jump on trial expansion for Modi-1 vaccine |
| 31/7/2023 | 07:00 | UKREG | Scancell Holdings Plc Modi-1 trial open for expansion in CPI combination |
| 13/7/2023 | 09:14 | UKREG | Scancell Holdings Plc Extension of exercise period for CEO share options |
| 10/7/2023 | 11:45 | ALNC | IN BRIEF: Scancell to focus on cancer vaccine assets amid trial data |
Scancell (SCLP) Share Charts1 Year Scancell Chart |
|
1 Month Scancell Chart |
Intraday Scancell Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/9/2023 | 14:27 | Scancell - Pot of Gold or POS? | 6,238 |
| 23/9/2023 | 13:38 | Using immunology to fight cancer. | 57,573 |
| 13/2/2023 | 08:10 | On the Slingshot, Scancell | 1 |
| 22/11/2022 | 14:00 | Using immunology to fight cancer. | 1 |
| 11/9/2022 | 11:09 | Question | 12 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 23/9/2023 07:50 by inanaco inanaco - 22 Sep 2023 - 16:03:24 - 6161 of 6179 Scancell - Pot of Gold or POS? - SCLPlook we all know the share price fluctuates most of the time because folks get bored, can't read RNS or just dont have a clue about the science ... all they do is look at elliots waves and make a guess buy or sell agreed ? so share price is not the benchmark to value anything other than sentiment |
Posted at 21/9/2023 07:44 by inanaco colin advising Ruck .....Ivyspivey - 12 Jul 2023 - 07:33:26 - 4686 of 6049 Scancell - Pot of Gold or POS? - SCLP Morning as you say Ruck it was a general warning to patiently wait for news and not to go in deep based on the conviction of self appointed experts which over the years here have proved false flags. You can of course based on individual trading styles or combination of there of buy or sell based on sentiment and TA. I keep it simple I buy when I expect the price to go up- it may be short or long term and I might get it right or get it wrong as none of us can predict with certainty as some claim. So if I bought at 22p at a time of “euphor I am surprised that WW a self proclaimed very experienced investor who has sat through loads of investor presentations appears to comment like a complete novice. I thought the LD talk was low key especially given the anticipated hype and that us my judgement call whilst others have taken a different view. The only reaction that matters is the market reaction and the likes of a Lozan have called that much better than likes of Nana. I take no pleasure in that as it means that Modi has not fully delivered for the trial patients and yes there were some encouraging signs but like Bermuda who most people respect as a great judge of informed and balanced opinion my general feeling was of disappointment and that feeling I though echoed by LD performance. Others can disagree which is fine that is what the boards are for but judging by the response from likes of Nana and WW etc they do seem very rattled. Bit like buying a SARF London flat at £500k looks on the surface like a foolish move but if you sell it for £1m then it is a smart move but if it follows the trajectory of the SCLP share price then it will turn out to be a bad move. So perhaps you might be better off listening to advice of others and consider things like Elliot Waves as having an open mind may just improve your decision making ability. GLA |
Posted at 20/9/2023 19:05 by ivyspivey Evening Ruck the guy is a total clown and now he has spilt the beans on how he works out his average not as most people do by only including dealings in a specific share but by including non SCLP related investment returns as he nsy have funded them via profits from trading SCLP.But of course he only includes his dealings but no one else’s so when I repeatedly said I bought at 5 p and sold at 8p but then invested the money in AVCT which went up on average 5 fold then he criticised me for selling at 8p when the share price rose higher rather than acknowledging you can actually invest those proceeds like he did with his car park and benefit overall but of course because he did it then it needs to be included and he has used it to lower his average on SCLP. So that tells us his real average on SCLP is way above what he claims and much more like 15-20p so after 12 years he is still not showing an investing profit so what a total failure. He then criticises “ traders” but that is exactly what he has done and of course thise traders make only pennies when he has not got a clue how much they make plus the concept of compounding which he knows nothing about. Like you making the big profit on that occasion which he dismissed. You simply can’t believe a word he says |
Posted at 19/9/2023 15:13 by ruckrover plasybryn"If we were around 23p in March 2021 how is it we aren’t well north of there now given these stunning data results." Well it's not dilution - 818.4M shares today compared with 815.2M in March 2021. The share is entirely driven by sentiment, fear, greed , news and lack of news. Since March 2021, the share sat between 19p and 22p for nearly a year. It then drifted down to 11p by April 2022 on no news whatsoever. News that the MODI1 trial was open gave it a lift in April 2022, but it drifted back to the 11-13p range by October. In November we got wind of a patient on the trial who had had a 55% reduction in tumour. This propelled the share price into the mid 20s. Then we had news that the same patient had been taken off the trial as treatment had stopped working. This caused fear amongst the faithful and a bit of a sell off ensued, taking us to the recent single digit share price Todays RNS has hopefully put us back on track to where we should be - 28p-32p as valued by the more balanced Trinity Delta research. Of course, back in October 2012, we hit 60p. Back then there was just SCIB1 in the clinic with Moditope being a recent addition. Since then, we have had MODI1 in the clinic, SCIB1 back in the clinic as combo, some compelling early data from the trial, MODI2, Avidimab, GlyMab, GenMab deal and Covitity. So no ryhmn or reason as far as the share price goes. |
Posted at 30/8/2023 09:07 by marcusl2 I’d forget RC365 shares! I think these 2 penny stocks could be next. In the middle of June, RC365 Holdings (LSE:RCGH) shares were trading at 25p. They’ve since exploded higher, currently trading at 125p. Clearly, there’s higher volatility when investing in penny stocks. Yet the potential rewards can be huge. Even though RC365 shares could keep flying higher, I’ve probably missed the big move. But here are two other stocks I believe have the potential to rally.Waiting for a move The other penny stock that I’m looking at is Scancell Holdings (LSE:SCLP). The stock has fallen by 24% over the past year, with a share price of just 9.5p. The company is a clinical stage biopharmaceutical company. Ideally, it needs to be able to take products from research stage, through clinical trials and get them all approved in order to generate sizeable profits. Currently, the business is loss-making. It doesn’t have any revenue coming in through the door, but has sizeable expenses to fund the research and trials. Although this is a risk, it’s the same practice that all in the same business line go through. Yet on the other hand, it has £24m cash on hand (as of the latest report). It burned through £4.4m in the previous six months, so it has a big buffer to keep running operations for a while. In the meantime, I believe it has a good shot at taking either Modi-1 or SCIB1 products to the market in 2024. Modi-1 had a recent 44% disease control rate with test patients of aggressive cancer that had exhausted other options. This shows me that the potential take-up of the product if it reaches the market could be very large. As soon as investors get a smell that this could be the case, I’d expect the share price to rally. |
Posted at 09/8/2023 12:32 by 2tyke As far as SCLP share price goes.....one person and one person only has called it correctly.....drum roll.....the elliottician.It's a results based business. All about intellectual honesty....you have it...or you don't ! |
Posted at 08/8/2023 11:56 by 2tyke Ivy,Yes you're correct, it's impossible to get through to the closed mind brigade if which inanaco is a member. As far as 'external news' goes....everything has an effect. But the volatility of news events is trumped by the sentiment which drives the price. When one becomes proficient at EW, one can understand why good news fails to rally the share price In a second wave, which has likely just ended from 29p down to 9p, any short term spike on good news quickly fades as sentiment takes the share price lower. That position changes in wave 3, which we should be now in. Any good news should 'supplement' positive share price sentiment and help move prices higher even quicker. So it's not a case of me saying news doesn't have an effect Ivy...it's just understanding the human psychology of the wave principle. It's absolutely key to following asset prices correctly. |
Posted at 04/8/2023 12:57 by 2tyke I'll repeat that knocker...An RNS is a tardy recognition of forces that have been apparent to a share price for quite some time. It's one of the most informed and correct statements you'll hear on a bb. Think about SCLP share price dropping from 29p. All the bulls waiting eagerly for the next RNS for boom 💥 When it came ..they changed their tunes. The RNS was a late recognition of sentiment. It didn't drive the price. It was used to try and 'explain it' in hindsight. |
Posted at 04/8/2023 10:34 by 2tyke Looks like the clappers on both BB's are demonstrating the misconceptions that resulted in them being LTH and suffering the painful losses from 29p. Yes...it is always a LOSS, however you try to slant it !Chill and inane trying to justify their euphoria with £8 a share being a doddle ! The clappers bb wanting RNS's to have more 'user-friendly' headings...lol Look ....I'll help you all out again. The thing is this. Traders are not governed by future potential. No. They are governed by mass psychology. You LTH's mistakenly expect traders (who actually control the SP) to think like yourself. They really don't. So you can bang on about the science or the potential all you want to your hearts content....but the share price will follow the form it takes. Have you seen any evidence of science or potential driving the share price over the last decade or so ? Biontech didn't become the price it is overnight. The waves grew in exactly the required form. Third waves of very high degree can be exponential. It takes time. Stock prices have a 'form' So the clappers bb can forget user friendly headlines for RNS's. Just like corporate earnings, RNS's are YESTERDAYS NEWS. Think about it. They tell you nothing of the future...and even less about the future share price If you want to anticipate what traders will do next, you need to understand collective psychology....not yet and think of ways the company can write notifications so that you can kid yourselves !! |
Posted at 04/8/2023 09:10 by chilltime £8 per share, why scoff at that and mock others, other than for the sake of trying to do exactly that, mock others.Scancell could be worth a lot more than £8 per share. Genmab in its early days is like a sister to Scancell they were/are like mates in a pub, running similar businesses. Genmab bumped along low level then hit the right mix, raising in value over a 100 times from about 12 years ago to now. Market cap now about £21 billion, Genmab was a Scancell trying to find the magic mix. The rest is history. All options in play. like for like (Genmab) that would be about a £21 share price for Scancell. Genmab revenue Q1 2023 35% up from Q1 2022 was £342m. Yet some posters scoff at the limitation of some therapies to about £1B revenue potential to Scancell. Yet Genmab hit over £20b in market cap terms. So to suggest £8 per share is a ridiculous fantasy is equally ridiculous when comparing it to actual progressing companies in the sector. Cash should come in any form from fund raising to payments. EG the Genmab Glymab carries up to 3 separate up-front payments, for each aspect going into phase 1. That Glymab has a 4th aspect available to others, which is probably what the news on that topic is about, it's probably that Glymab with data available. Up-front payments could come from the other Glymabs being looked at, plus deals for other aspects of Scancell. It's a lottery on timing and progress. BUT the lottery odds of winning keep dropping, as each news says promising, progress etc. Evidence that untreatable cancer sufferers, where everything else has failed, are seeing progress, sometimes significant progress. The hard nut ovarian saw a positive impact in some way on 44% of those that took Modi. The remaining cancers are likely to see higher rates in a sector looking for 25%. Higher rates in the hard to treat sector NOT the level playing field of those that have gone before. So £8 isn't fiction, it could well be way below the actual depending on how things progress, it could go bust, but we have the advantage of accounts, news and results to determine, the likely moves in the future, boom or bust. Like a gold rush the mRna scene has become saturated, competitors for the various aspects. Scancell has it's own sector, a new way which is safer and potentially a higher grade. Very few, if any are in the Scancell space, DNA, epitopes and so on. Time will tell, but 2023 and the news to come is exciting, any one of the aspects could start the Gemmab type impact. Market sentiment and forum exchanges have no impact on whether a treatment works or not, but they do impact the short term share price. If big news success comes the share price doesn't wait for the revenue to actually arrive, before the share price takes off. The race to buy shares and sentiment does that, not actual revenues. Sentiment and market moves can send share prices well ahead of of future revenue. It's the sector that matters, Bios are of huge interest when the right news hits. Some public low level bios will do that, professor James who looked at dozens for months told, Vulpes Scancell looks like most likely, with unprecedented results in some aspects. Thus, to me, having a look myself, I believe the prospects look very good. The potential is huge. |
| Your Recent History | |||||||
Register now to watch these stocks streaming on the ADVFN Monitor.
Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Log in to ADVFN
Register Now | |||||||
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
| V: D: 20230924 13:39:06 |
